Chronic rhinosinusitis with nasal polyps unresponsive to medical therapy in a patient with asthma
A 45-year-old woman with aspirin-exacerbated respiratory disease (AERD), asthma, and chronic rhinosinusitis with nasal polyps has had two prior endoscopic sinus surgeries. She now has recurrent polyposis, anosmia, and daily nasal obstruction despite 3 months of high-volume saline irrigation, intranasal corticosteroids, and a short course of oral prednisone. She is on a biologic for asthma. She asks whether another surgery will help and whether she should stop the biologic.
1. How do you approach the decision for revision sinus surgery versus continued medical therapy, and what role does the biologic play?
Read the worked answer
This is type 2 inflammatory CRSwNP with AERD, recurrent after two surgeries, with anosmia and obstruction despite appropriate medical therapy.
Decision-making:
- Confirm adherence and technique with saline irrigation and intranasal steroids; verify the prednisone course was adequate.
- Optimize topical therapy (e.g., budesonide rinses) and consider allergy evaluation.
- The biologic (e.g., anti-IgE, anti-IL-5, or anti-IL-4R) is a key controller; do not stop it. Coordinate with pulmonology/allergy. Biologics can reduce polyp burden and may reduce the need for surgery, but response varies.
- Revision surgery is reasonable if symptoms persist despite maximal medical therapy and biologic, especially with obstructive disease and anosmia; however, surgery in AERD has high recurrence, so set expectations.
- Consider a CT scan to assess disease extent and surgical planning.
Judgement point: the question is not 'surgery or biologic' but sequencing and optimization; avoid stopping a controller that may be helping asthma and polyps.
2. What specific risks and counseling points apply to revision sinus surgery in AERD?
Read the worked answer
Risks and counseling:
- High recurrence rate of polyps despite surgery; patients should expect possible need for further procedures.
- AERD patients may have severe intraoperative and postoperative inflammation; ensure steroid coverage and coordination with asthma management.
- Bleeding risk and need to hold anticoagulants; assess.
- Risk of synechiae, ostial stenosis, and skull base injury, especially with distorted anatomy from prior surgery.
- Anosmia may not fully recover.
- Emphasize continued medical therapy and biologic after surgery; surgery is an adjunct, not a cure.
Judgement point: revision surgery can improve symptoms and access for topical therapy, but the underlying type 2 inflammation persists, so long-term medical control and realistic expectations are essential.